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1. Introduction 
Gastric cancer represents the second leading cause of cancer related death (after lung cancer) 
despite a global decline in both its incidence and mortality since the late half of the 20th 
century (Kelley & Duggan, 2003; Zheng et al., 2008). This type of cancer continues nowadays 
to be a major health problem due to the slow decrease in incidence in Asia and its high 
mortality in the western countries (Roukos et al., 2002). The overall prognosis is reserved, 
depending on the TNM stage in the moment of diagnosis and somewhat on its histological 
type (Lauren, 1965). 
Based on morphological characteristics focused on gland formation and histogenetic 
background, gastric adenocarcinomas are divided into intestinal and diffuse types using the 
Lauren classification system (Lauren, 1965), or as differentiated and undifferentiated using 
the Nakamura classification system (Nakamura et al., 1968). Intestinal-type adenocarcinoma 
is considered to be equivalent to differentiated adenocarcinoma and the diffuse-type to the 
undifferentiated adenocarcinoma. 
These different types of gastric carcinomas express particular biological behaviours. 
Helicobacter pylori infection leads to the development of chronic atrophic gastritis and 
intestinal metaplasia (Byrd et al., 1997). Usually the intestinal-type gastric carcinoma arises 
on the background of intestinal metaplasia (Stemmermann, 1994; Tahara, 1993), and, by 
contrary, the diffuse-type on the background of gastric mucosa without intestinal 
metaplasia (Nakamura et al., 1968). The diffuse-type, as classified according to the Lauren 
system (non-solid type of poorly differentiated adenocarcinoma and the signet-ring cell 
carcinoma according to a Japanese classification system) (Japanese Gastric Cancer 
Association, 1996), do not show glandular formation, can be further divided into two 
subtypes. In the first one, the tumor is predominantly composed of signet-ring cells (>50%) 
(signet-ring cell carcinomas) and in the other one, the adenocarcinoma contains few signet-
ring cells (<50%) (non-signet ring cell carcinomas). Although these histological types can 
usually be distinguished using standard stainings, new advances in histochemical and 
immunohistochemical reactions using gastric and small intestinal cell markers determined 
emerging of gastric cancer classification into different phenotypes, according to mucin 
expression (Tatematsu et al., 1990). 
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Much effort is being carried out to identify markers with biological and therapeutical 
significance in gastric cancer. Mucins are expressed by various epithelial cell types, both 
normal and malignant.  Mucins, high-weight glycoproteins, represent major components of 
the mucus layer which protects the gastric epithelium against chemical and mechanical 
aggressions (Corfiefd et al., 2000; Moniaux et al., 2001). In humans, at least 14 genes were 
identified, coding proteins of mucins, called MUC1, MUC2, MUC3, MUC4, MUC5AC, 
MUC5B, MUC6, MUC7, MUC8, MUC9, MUC11, MUC12, MUC13 and MUC16 (Pinto-de-
Sousa et al., 2002; Silva et al., 2002). They are classified into two groups: membrane bound 
including MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13 and MUC 17, and secreted or 
gel forming including MUC2, MUC5AC, MUC5B and MUC6 (Fowler et al., 2001). All these 
mucins present common structural characteristics, but are distinct in their tandem repeat 
peptides. Abnormal expression of mucins has been reported to accompany cancer 
development, influence cellular growth, differentiation, transformation, adhesion, invasion 
and immune surveillance (De Bolos et al., 1995). 
MUC1 is involved with cell signaling, immuno-regulation and inhibition of cell-cell and cell-
matrix adhesion (Rakha et al., 2005; Wesseling et al., 1996). MUC1 cytoplasmic domain has 
been observed to interact with ǃ-catenin through a similar mode found in E-cadherin, by 
this way inhibiting the formation of E-cadherin- ǃ-catenin complex (Yamamoto et al., 1997). 
By this action, MUC1 may participate in tumor cell detachment, invasion and metastases, 
being associated with aggressive tumor behavior and poor prognosis. There have been 
reported interactions between MUC1 and members of EGFR family (Rahn et al., 2001). The 
cytoplasmic domain has a role of signaling mediator of tyrosine kinase receptors 
(phosphorylated MUC1-Grb2/SOS complex) (Schroeder et al., 2001). MUC1 is present on 
the apical surface of secretory epithelia, but in the malignant tissues is variable in amount 
and cellular localization (Pandey et al., 1995). The high aberrant MUC1 expression in tumors 
leads to antigenically recognizable epitopes on the MUC1 molecules and stimulation of the 
immune response, making MUC1 a potential immunotherapeutic target (Gendler, 2001). 
MUC2 and MUC5AC are important proteins for producing the mucus that protects and 
lubricates epithelial surfaces. MUC2 is the major secretory glycoprotein expressed 
abundantly by intestinal and airway epithelium (Gum et al., 1994). Its expression is a 
common feature of all mucinous carcinomas derived from different organs, including 
stomach, colon, breast and prostate, acting as a potential prognostic marker (Utsunomiya et 
al., 1998; Yamashita et al., 1993; Zhang et al., 1998).  
MUC5AC is found mainly in the mucosal layer of the cardia, fundus and antrum of the 
stomach, with the role of epithelia protection (Ho et al., 1995). Tumor phenotypes are 
classified on the basis of the expression of various markers, such as CD10 as a marker for the 
brush border on the luminal surface of enterocytes, mucin 2 (MUC2) as a marker of 
intestinal goblet cells, MUC5AC or human gastric mucin (HGM) as a marker of surface 
gastric epithelium (foveolar cells) and MUC6 as a marker for pyloric glands (Namikawa & 
Hanazaki, 2010).  
CD10 and MUC2 are considered diagnostic markers of the intestinal phenotype and 
MUC5AC, HGM and MUC6 are markers of the gastric phenotype. Gastric cancer 
phenotypes can be classified into four groups, depending on the combination of mucin 
expression: intestinal type, gastric type, combined type and unclassified type (Shiroshita et 
al., 2004). 
Intestinal metaplasia can be divided into incomplete (precancerous lesion), consisted by the 
presence of goblet cells in the gastric gland, and complete (not a precancerous lesion), 
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consisted by the presence of both enterocytes and goblet cells (Kawachi et al., 1974; Segura & 
Montero, 1983; Tosi et al., 1993). Based on the type of intestinal metaplasia, there are four 
phenotypes of gastric cancer: complete intestinal type, incomplete intestinal type, gastric 
type and unclassified type. The complete intestinal type is positive for CD10 and MUC2, 
and negative for MUC5AC. The incomplete intestinal phenotype is positive for CD10 and 
MUC5AC, or positive for MUC2 alone. The gastric type is positive for MUC5AC, and 
negative for CD10 and MUC2. Unclassified phenotypes are negative for CD10, MUC2, 
MUC5AC and MUC6. This classification based on mucin phenotype is important for 
assessing the biological behavior of gastric carcinomas and different therapeutic options 
(Namikawa & Hanazaki, 2010). 
Gastric-type mucins are mucins specific to the gastric mucosa, although differentiated 
gastric adenocarcinomas change their mucin phenotype as they grow and invade deeper 
into the gastric wall. Recent reports reveal an incidence of 7.9-23.9% for the gastric-type 
differentiated adenocarcinomas among early gastric cancers (Kabashima et al., 2002; Koseki 
et al., 2000; Matsuoka et al., 2003). This type of early cancer tends to form larger tumors and 
exhibit higher rates of submucosal invasion in comparison with the intestinal-type 
(Matsuoka et al., 2003). 
Gastric- and intestinal-types of differentiated gastric adenocarcinoma present differences in 
terms of their biological behavior. Usually, gastric-type tumors show scirrhous infiltration 
and intestinal-type carcinomas show a solid growth inside the wall (Oda et al., 2003; 
Shimoda et al., 1991). Some authors reported a significantly poorer prognosis in patients 
with advanced gastric cancer presenting gastric-type tumors vs. intestinal-type carcinomas, 
associated with increased malignant potential in the early phase of invasion and metastasis 
(Tajima et al., 2001). Koseki et al. (2000) have reported a significantly higher incidence of 
lymphatic invasion, venous invasion, and lymph node metastasis in the gastric-type. For 
these reasons, even in the early phase of the gastric-type, the decision to perform endoscopic 
mucosal/submucosal resection or minimal surgical procedures as a curative treatment 
should be carefully taken (Namikawa & Hanazaki, 2010).  
The undifferentiated gastric adenocarcinoma show no clinicopathological differences 
between gastric and intestinal phenotypes. However, gastric-types present different growth 
patterns compared with intestinal-type tumors (Kabashima et al., 2005), showing a tendency 
to spread through the middle layer of the mucosa. 
Recent studies have reported a different genetic background of patients with differentiated 
gastric adenocarcinomas for gastric-type compared to intestinal-type (Endoh et al., 2000; 
Fiocca et al., 2001; Matsuoka et al., 2003; Sugai et al., 2004). Overexpression of p53 protein is 
a common feature in differentiated adenocarcinoma (in both gastric- and intestinal 
phenotypes), but is rare in undifferentiated carcinoma (Matsuoka et al., 2003; Sugai et al., 
2004). Data suggest that differentiation to gastric gland cells is related to the presence of 
microsatellite instability (MSI), whereas differentiation to intestinal epithelial cells is related 
to mutations in APC gene (Endoh et al., 2000; Tajima et al., 2006; Yamazaki et al., 2006). 
Usually, the phenotype of gastric cancer tends to imitate the surrounding mucosa, with 
gastric-type cancers arising in areas expressing gastric-type or mixed-type mucins 
(Kabashima et al., 2000). Intestinal metaplasia surrounding gastric-phenotype of 
differentiated adenocarcinoma seems to be immature or incomplete, compared with gastric-
intestinal or intestinal phenotype (Egashira et al., 1999). 
Pinto-de-Sousa et al (2002) showed that the mucin phenotype is associated with the tumor 
site. In the study of Toki et al (2010), the signet ring cell carcinomas and non-signet ring cell 
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carcinomas were most frequently encountered in the upper or middle segments of the 
stomach. Over 95% of the advanced gastric cancers had either a G or GI phenotype. Pinto-
de-Sousa et al (2002) studied the mucin phenotypes of 23 diffuse-type adenocarcinomas and 
showed that the MUC5AC expression rate in these tumors was significantly higher than that 
in the unclassified and expansive adenocarcinomas. Reis et al (1997), studying the 
expression of MUC5AC in early gastric cancers, demonstrate at least some G phenotype 
cells in the initial stages of the tumors. 
Some studies show that the expression rates of the GI and I phenotypes in the cases of 
undifferentiated advanced gastric cancers were encountered in over half of the cases (Baresi 
et al., 2006; Tajima et al., 2001; Toki et al., 2010). Studies reported that the progression of the 
signet ring cell carcinomas was associated with a phenotype shift from the G-type to the I-
type in order to progress to the deep layer (Bamba et al., 2001; Tian et al., 2007; Yamachika et 
al., 1997; Yamagishi et al., 2004). It is also suggested that the morphological features of the 
signet ring cells change and are subsequently classified as non-signet ring cell carcinomas 
during tumor progression (Toki et al., 2010). 
In the present research we aimed to assess the profile of mucins in gastric carcinomas 
through immunohistochemical reactions using anti- MUC1, MUC2, and MUC5AC 
monoclonal antibodies. The purpose of this study is to compare the expression of mucins 
with clinicopathological factors and outcome of patients. 
2. Material and method 
From the total of 256 patients (186 males and 79 females), diagnosed clinically and 
histopathologically with gastric cancer in the period 1998-2002 that underwent surgical 
interventions in the Departments of Surgery of the Emergency County Clinical Hospital 
Timisoara, there were 67 patients selected. A prospective study was performed on this 
group, regarding the evolution and aggressiveness of gastric cancer, on a period of 5 years. 
Surgical interventions, performed with curative or palliative intention, were not preceded 
by chemotherapy or radiotherapy. The patients or their relatives were contacted 
periodically, on the phone or by medical letter, at 6-month intervals, survival being 
monitored on a variable period, between one month and 68 months. Patients who died 
postoperatively through various complications, or due to other conditions, were excluded 
from the study. Clinical and morphological (macroscopic and microscopic) data were 
collected for each case. Gastric carcinomas were classified and interpreted according to the 
evaluation protocol recommended by the American Joint Committee on Cancer (AJCC) and 
International Union against Cancer (UICC). 
Survival time was calculated from the month of surgery until the month of death or 
confirmation of survival, and survival rate was represented by the percentage of survivals at 
the end of the interval monitored (in years and months). Out of the total of cases included in 
the prospective study, 6 patients died at variable intervals, between 7 and 26 months, due to 
other medical causes, being excluded from the study. 
Immediately after excision, specimens were fixed in 10% neutral buffered formalin, 
embedded in paraffin wax, cut into 3 μm paraffin sections and stained with haematoxylin 
and eosin (HE) for routine light microscopy. For immunohistochemical staining, additional 
3 μm thick sections were cut from paraffin-embedded tissue and placed on poly-L-lysine-
coated glass slides. For the determination of mucin phenotypes, immunostaining was done 
for MUC 1 (monoclonal antibody Ab-5, MH1, Thermo Scientific), MUC2 (monoclonal 
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antibody Ab-2, M53, Thermo Scientific) and MUC5AC (monoclonal antibody Ab-1, 45M1, 
Thermo Scientific). Immunohistochemistry used the UltraVision Detection System, 
HRP/DAB (Ready-To-Use).  The nuclear counterstaining was accomplished using Mayer’s 
hematoxylin. According to their immunoreactivity, the cases were classified in 2 categories: 
• negative cases (negative or positive immunoreactions in less than 5% of cells examined); 
• positive cases (positive immunoreactions in more than 5% of cells examined). 
Statistical analysis was performed using STATA 9.2 software (Statacorp, Texas, USA). 
Frequencies and percentages are shown for categorical data. Chi-square test was used to 
compare categorical data.  Survival time was calculated as the time from cancer diagnosis to 
death, censoring at the date of last contact. The Kaplan-Meier method was used to compute 
5-year survival rates and disease-specific survival curves were drawn. Differences between 
survival curves were determined by log-rank test. Survival analysis was performed using a 
Cox proportional hazards model. A P-value <0.05 was considered statistically significant, 
and hazard ratios (HR) with their respective 95% confidence interval (CI) were calculated. 
3. Results 
The final group consisted of 61 patients (43 males and 18 females) who presented ages 
between 30 and 80 (average age = 59.34 years). The main clinicopathological features of 
cases of gastric cancer investigated are presented in Table 1. In the peritumoral mucosa, 
MUC1 reactivity was detected in specialized glands of the gastric body (Fig. 1), in the 
pyloric glands (Fig. 2), and at the level of the antrum, in surface mucous cells and mucous 
neck cells. 
 
Clinicopathological factors No. of cases 
Males 43 
Females 18 
Average age (min-max) years 59.34 (30-80) 
Location 
Antrum 31 
Body 15 
Pangastric 10 
Eso-cardial 2 
Gastric stump 3 
Early carcinoma 5 
Advanced carcinoma 56 
Borrmann 
I 5 
II 20 
III 22 
IV 9 
pTis/T1/T2/T3/T4 4/6/7/21/23 
pN0/N1/N2/N3 18/16/23/4 
pM0/M1 47/14 
Table 1. Clinicopathological characteristics of gastric cancers studied 
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MUC5AC is expressed strongly in the foveolar epithelium of gastric antrum and body (Fig. 
3 and Fig. 4). MUC2, an intestinal-type mucin, was identified only on foci of intestinal 
metaplasia of gastric mucosa (in goblet cells – Fig. 5).   
The expression of mucins in gastric carcinomas studied is heterogeneous and includes 
mucins synthesized normally by the gastric mucosa, as well as intestinal mucins expressed 
“de novo”. We identified 41 cases with positive immune reactions for MUC1 (67.2%), 25 
cases with positive reactions for MUC2 (40%), and 43 cases for MUC5AC (70.5%)  
(Graphic 1). 
 
 
Fig. 1. MUC1-positive immunoreaction in specialized glands of the gastric body. DABx200. 
 
 
Fig. 2. MUC1 positive immunoreaction in pyloric glands. DABx200. 
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Fig. 3. MUC5AC-intensely positive immunoreaction in the gastric foveolar epithelium. 
DABx200. 
 
 
 
 
 
Fig. 4. MUC1-positive secretion in gastric glands; negative metaplastic foci. MUC1 
immunoreaction, DABx200. 
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Fig. 5. MUC2-positive immunoreaction on foci of intestinal metaplasia. DABx200. 
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Graphic 1. Expression of mucins in gastric carcinomas 
3.1 Immunohistochemical expression of MUC1 in gastric carcinomas 
MUC1 antigen is expressed in most cases at the apical pole of cells and intraluminally (Fig. 
6), and occasionally diffusely intracytoplasmatic (Fig. 7).  
Our results do not show a relationship between the expression of MUC1 and gender of 
patients, but reveal greater immunopositive results in patients with ages over 61 (78.1%) in 
comparison with patients under 60 (55.2%) (P=0.057 borderline statistical significance) 
(Table 2). According to the location of tumors, we noted MUC1 positive immunoreactions in 
64.5% of antral carcinomas, in 73.3% of body carcinomas, in 70% of carcinomas extended in 
the entire stomach, in 66.7% of carcinomas developed on the gastric stump and in 50% of 
carcinomas of the cardia. 
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Clinicopathological factors 
MUC1 
P - 
n=20 
+  (%) 
n=41 
Gender 
Males 13 30 (69.8%) 
0.511 
Females 7 11 (61.1%) 
Age 
≤ 60 years 13 16 (55.2%) 
0.057 ≥ 61 years 7 25 (78.1%) 
Location 
Antrum 11 20 (64.5%) 
0.956 
Body 4 11 (73.3%) 
Pangastric 3 7 (70%) 
Cardia 1 1 (50%)  
Gastric stump 1 2 (66.7%) 
Table 2. Relationship between gender of patients, age of patients and MUC1 expression 
Classifying the tumors studied according to Lauren, we observed the greater frequency of 
MUC1-positive immune reactions (without reaching statistical significance) in carcinomas 
with glandular differentiation (73.7% - Fig. 8) (Table 3). The diffuse type of carcinoma 
became positive in 53% of cases (Fig. 9), and for the mixed type we obtained an intermediate 
value (66.7%). 
 
 
Fig. 6. MUC1-positive immunoreaction intra luminally and at the apical pole of malignant 
cells. DABx200. 
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Fig. 7. MUC1 synthesis at the apical pole and intracitoplasmatical. MUC1 immunoreaction, 
DABx400. 
Classifying the tumors studied according to Lauren, we observed the greater frequency of 
MUC1-positive immune reactions (without reaching statistical significance) in carcinomas 
with glandular differentiation (73.7% - Fig. 8) (Table 3). The diffuse type of carcinoma 
became positive in 53% of cases (Fig. 9), and for the mixed type we obtained an intermediate 
value (66.7%). 
 
 
Fig. 8. Intestinal type of gastric carcinoma. MUC1 immunoreaction, DABx400. 
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Fig. 9. Diffuse type of gastric carcinoma. MUC1 immunoreaction, DABx400. 
From the histological forms, tubular and papillary adenocarcinomas (Fig. 10) became 
positive in a great number of cases (78.6% and 80%). For the mucinous adenocarcinoma we 
encountered 62.5% positive cases. The poorly differentiated forms, such as signet-ring cell 
carcinoma and anaplastic carcinoma (Fig. 11 and 12), expressed MUC1 in 53% and 33.3% of 
cases. In our study, the differences in MUC1 expression between various histological types 
were not statistically significant. 
 
Clinicopathological factors 
MUC1 
P -  
n=20 
+ (%)  
n=41 
Lauren classification 
Intestinal type 10 28 (73.7%) 
0.318 Diffuse type 8 9 (53%) 
Mixed type 2 4 (66.7%) 
Histological type 
TA 6 22 (78.6%) 
0.265 
PA 1 4 (80%) 
MA 3 5 (62.5%) 
SRCC 8 9 (53%) 
AC 2 1 (33.3%) 
Tumor grade 
G1 0 2 (100%) 
0.468 G2 8 12 (60%) 
G3 12 27 (69.2%) 
Lymphovascular 
invasion 
Present 13 25 (65.8%) 
0.761 
Absent 7 16 (69.6%) 
TA-tubular adenocarcinoma; PA-papillary adenocarcinoma; MA-mucinous adenocarcinoma; SRCC- 
signet-ring cell carcinoma; AC- anaplastic carcinoma 
Table 3. Relationship between the histological type, tumor grade, lymphovascular invasion 
and expression of MUC1 
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Fig. 10. Papillary adenocarcinoma. MUC1 immunoreaction, DABx200. 
 
 
Fig. 11. Anaplastic carcinoma. MUC1 immunoreaction, DABx200. 
The immunohistochemical expression of MUC1 is not correlated with the tumor histological 
grade and lymphovascular invasion. G1 carcinomas became positive for MUC1 in 100% of 
cases, but the result obtained could be influenced by the small number of cases included in 
this category. 
From our data does not result a correlation between the MUC1 positive immune reaction 
and the level of tumor invasion (pT stage), the presence of distance metastases (pM stage) 
and pTNM staging (Table 4). However, we noted a largerer number of positive 
immunoreactions in cases with lymph node metastases (31 carcinomas – 72.1%) in 
comparison with tumors without metastases (10 cases – 55.6%), although not reaching 
statistical significance. 
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Fig. 12. Anaplastic carcinoma. MUC1 immunoreaction, DABx400. 
Our results regarding survival of patients at 5 years demonstrate the role of MUC1 over-
expression as a prognosis factor in gastric carcinomas. Patients with carcinomas which 
became positive for MUC1 survived significantly less than patients with MUC1 negative 
carcinomas (12.2% vs. 25% at 5 years) (P=0.0047) as shown in Graphic 2.  
 
Clinicopathological factors 
MUC1 
P - 
n=20 
+ (%) 
n=41 
pT 
Tis 0 1 (100%) 
0.870 
T1 1 3 (75%) 
T2 3 6 (66.7%) 
T3 7 10 (58.8%) 
T4 9 21 (70%) 
pN 
N0 8 10 (55.6%) 
0.636 N1 5 11 (68.7%) 
N2 6 17 (74%) 
N3 1 3 (75%) 
pM 
M0 16 31 (66%) 
0.702 
M1 4 10 (71.4%) 
pTNM 
0 0 1 (100%) 
0.884 
IA 1 2 (66.7%) 
IB 1 4 (80%) 
II 2 5 (71.4%) 
IIIA 3 8 (72.7%) 
IIIB 2 6 (75%) 
IV 11 15 (57.7%) 
Table 4. Relationship between TNM staging and expression of MUC1 
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Graphic 2. Survival at 5 years according to the MUC1 expression 
A significant difference was also obtained by calculating the average survival in months, in 
the postoperative period, between the two types of patients (Graphic 3): 
• for patients with MUC1-positive carcinomas: 12 months;  
• for patients with MUC1-negative carcinomas: 28.5 months. 
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Graphic 3. Average survival of patients according to the MUC1 expression 
Patients with MUC1 positive carcinomas were about two times more likely to die than those 
with MUC1 negative carcinomas (HR=2.30; 95%CI: 1.24-4.26; P=0.008).  
3.2 Immunohistochemical expression of MUC2 in gastric carcinomas 
Positive immunoreaction for MUC2 was observed only in malignant cells (intracytoplasmic) 
and in goblet cells from foci of intestinal metaplasia of gastric peritumoral mucosa (Fig. 13). 
We did not note the synthesis of MUC2 in epithelial cells of the normal gastric mucosa. 
From the results obtained we conclude the absence of a relationship between the age and 
gender of patients and the immunohistochemical expression of MUC2 (Table 5). 
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According to the tumor location we noted MUC2 positive immunoreactions in 41.9% of 
antral carcinomas, 40% of gastric body carcinomas, 30% of pangastric carcinomas, and 25% 
of carcinomas developed on the gastric stump. We noted the tumors developed at the level 
of the cardia which expressed MUC2 in 100% of cases, suggesting the existence of a possible 
correlation between the overexpression of MUC2 and the cardial location of gastric 
carcinomas, but these data needs further confirmation by a larger number of cases. 
 
Clinicopathological factors 
MUC2 
P -  
n=36 
+  (%) 
n=25 
Gender 
Males 25 18 (41.9%) 
0.830 
Females 11 7 (38.9%) 
Age 
≤ 60 years 18 11 (37.9%) 
0.644 ≥ 61 years 18 14 (43.7%) 
Location 
Antrum 18 13 (41.9%) 
0.483 
Body 9 6 (40%) 
Pangastric 7 3 (30%) 
Cardia 0 2 (100%) 
Gastric stump 2 1 (25%) 
Table 5. MUC2 expression and clinicopathological factors in gastric cancer 
 
 
Fig. 13. Intracytoplasmic synthesis of MUC2 in tumoral cells and metaplastic foci. MUC2 
immunoreaction, DABx100. 
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Fig. 14. Intestinal-type of gastric carcinoma. MUC2 immunoreaction, DABx100. 
According to the Lauren classification, we noticed a greater immune positivity in intestinal-
type carcinomas (47.4% - Fig. 14) and in mixed-type carcinomas (50%), in comparison with 
diffuse-type carcinomas (23.5% - Fig. 15) (Table 6), but without reaching statistical 
significance. 
 
Clinicopathological factors 
MUC2 
P -  
n=36 
+ (%) 
n=25 
Lauren classification 
Intestinal type 20 18 (47.4%) 
0.225 Diffuse type 13 4 (23.5%) 
Mixed type 3 3 (50%) 
Histological type 
TA 17 11 (39.3%) 
0.052 
PA 3 2 (40%) 
MA 1 7 (87.5%) 
SRCC 13 4 (23.5%) 
AC 2 1 (33.3%) 
Tumor grade 
G1 1 1 (50%) 
0.859 G2 11 9 (45%) 
G3 24 15 (38.5%) 
Lymphovascular 
invasion 
Present 22 16 (42.1%) 
0.819 
Absent 14 9 (39.1%) 
TA-tubular adenocarcinoma; PA-papillary adenocarcinoma; MA-mucinous adenocarcinoma; SRCC- 
signet-ring cell carcinoma; AC- anaplastic carcinoma 
Table 6. MUC2 expression and clinicopathological factors in gastric cancer 
Overexpression of MUC2 is correlated (P=0.052 borderline statistical significance) with 
mucinous adenocarcinoma as histological form, being identified in 87.5% of cases (Fig. 16). 
From histological forms that are associated most rarely with the secretion of MUC2, we 
should mention the signet-ring cell carcinoma (23.5%). The data obtained are not suggestive 
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for a relationship between the tumor histological grade or lymphovascular invasion and the 
immunohistochemical expression of MUC2. 
 
 
Fig. 15. Diffuse type of gastric carcinoma. MUC2 immunoreaction, DABx200. 
 
 
Fig. 16. Mucinous adenocarcinoma. MUC2 intensely positive immunoreaction, DABx200. 
Based on the results obtained, we cannot point to the existence of a relationship between the 
pT, pN, pM, and pTNM factors, and the MUC2 immunoreaction in the gastric carcinomas 
examined (Table 7). 
The immunohistochemical expression of MUC2 does not influence survival at 5 years of 
patients (16% for MUC2 positive patients vs. 16.7% for MUC2 negative patients) (P = 0.7568) 
(Graphic 4).  
www.intechopen.com
 Gastric Carcinoma - Molecular Aspects and Current Advances 
 
218 
Clinicopathological factors 
MUC2 
P -  
n=36 
+ (%)  
n=25 
pT 
Tis 1 0 (0%) 
0.927 
T1 2 2 (50%) 
T2 5 4 (44.4%) 
T3 10 7 (41.2%) 
T4 18 12(40%) 
pN 
N0 10 8 (44.4%) 
0.953 N1 10 6 (37.5%) 
N2 14 9 (39.1%) 
N3 2 2 (50%) 
pM 
M0 28 19 (40.4%) 
0.871 
M1 8 6 (42.9%) 
pTNM 
0 1 0 (0%) 
0.988 
IA 2 1 (33.3%) 
IB 3 2 (40%) 
II 4 3 (42.9%) 
IIIA 6 5 (45.4%) 
IIIB 5 3 (60%) 
IV 16 10 (38.5%) 
Table 7. Expression of MUC2 and clinicopathological factors in gastric cancer 
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Graphic 4. Survival at 5 years according to expression of MUC2 
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Average survivals calculated in months show the lack of correlation between the prognosis 
of patients and the immunohistochemical expression of MUC2 (16 months for patients with 
MUC2-positive carcinomas, and 18,4 months for patients with MUC2-negative carcinomas) 
(Graphic 5). 
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Graphic 5. Average survival of patients according to expression of MUC2 
3.3 Immunohistochemical expression of MUC5AC in gastric carcinomas 
Immunohistochemical reactions performed with the anti-MUC5AC antibody have 
demonstrated the strong expression of the foveolar epithelium of the gastric antrum and 
body (Fig. 17), as well as in the cytoplasms of malignant cells from 43 gastric carcinomas 
(70.5% - Fig. 18). 
The results obtained do not show a relationship between the age or gender of patients and 
the expression of MUC5AC (Table 8). 
 
Clinicopathological factors 
MUC5AC 
P -  
n=18 
+  (%) 
n=43 
Gender 
Males 12 31 (72.1%) 
0.672 
Females 6 12 (66.7%) 
Age 
≤ 60 years 9 20 (69%) 
0.804 ≥ 61 years 9 23 (71.9%) 
Location 
Antrum 6 25 (80.6%) 
0.137 
Body 5 10 (66.7%) 
Pangastric 4 6 (60%) 
Cardia 2 0 (0%) 
Gastric stump 1 2 (66.7%) 
Table 8. Expression of MUC5AC and clinicopathological factors in gastric cancer 
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Fig. 17. MUC5AC intensely positive immunoreaction in the gastric foveolar epithelium. 
DABx100. 
 
 
Fig. 18. MUC5AC immune reactivity in the cytoplasm of malignant cells. DABx200. 
Analysis of MUC5AC according to location of tumors demonstrated the most frequent 
immunoreactivity of the antibody in antral carcinomas (80.6%) (without statistical 
significance). We identified positive immunoreactions in 66.7% of gastric body carcinomas, 
60% of pangastric carcinomas and 66.7% of carcinomas developed on the gastric stump. 
Cardial tumors did not express the MUC5AC antigen.  
The diffuse type of gastric carcinoma, as well as the signet-ring cell carcinoma, presented in 
a very high percentage (88.2%) MUC5AC positive immunoreactions (Tab. 9 – Fig. 19). Our 
results seem to show that MUC5AC is expressed mostly in the signet-ring cell carcinoma, 
but the differences between the histological subtypes did not reach statistical significance. 
According to the tumor histological grade, we noted 50% positive reactions in well-
differentiated carcinomas, 70% positive reactions in moderately differentiated carcinomas 
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and 71.8% in poorly differentiated carcinomas. We noted no relationship between the 
lymphovascular invasion and the expression of MUC5AC. 
 
 
Fig. 19. Gastric signet-ring cell carcinoma. MUC5AC immunoreaction, DABx400. 
 
Clinicopathological factors 
MUC5AC 
P -  
n=18 
+ (%) 
n=43 
Lauren 
classification 
Intestinal type 14 24(63.2%) 
0.165 Diffuse type 2 15 (88.2%) 
Mixed type 2 4 (66.7%) 
Histological type 
TA 20 18 (64.3%) 
0.082 
PA 2 3 (60%) 
MA 3 5 (62.5%) 
SRCC 2 15 (88.2%) 
AC 1 2 (66.7%) 
Tumor grade 
G1 1 1 (50%) 
0.958 G2 6 14 (70%) 
G3 11 28 (71.8%) 
Lymphovascular 
invasion 
Present 12 26 (68.4%) 
0.649 
Absent 6 17 (73.9%) 
TA-tubular adenocarcinoma; PA-papillary adenocarcinoma; MA-mucinous adenocarcinoma; SRCC- 
signet-ring cell carcinoma; AC- anaplastic carcinoma 
Table 9. Expression of MUC5AC and clinicopathological factors in gastric cancer 
Our results, similar with those obtained in analyzing MUC2, did not show the existence of 
a correlation between the level of tumor invasion, the presence of lymph node or distant 
metastases, the pTNM stage and the immunohistochemical expression of MUC5AC  
(Table 10). 
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Clinicopathological factors 
MUC5AC 
P -  
n=18 
+ (%)  
n=43 
pT 
Tis 0 1 (100%) 
0.489 
T1 1 3 (75%) 
T2 2 7 (77.8%) 
T3 3 14 (82.4%) 
T4 12 18 (60%) 
pN 
N0 5 13 (72.2%) 
0.992 N1 5 11 (68.8%) 
N2 7 16 (69.6%) 
N3 1 3 (75%) 
pM 
M0 14 33 (70.2%) 
0.930 
M1 4 10 (71.4%) 
pTNM 
0 0 1 (100%) 
0.985 
IA 1 2 (66.7%) 
IB 1 4 (80%) 
II 2 5 (71.4%) 
IIIA 4 7 (63.6%) 
IIIB 2 6 (75%) 
IV 8 18 (69.2%) 
Table 10. Expression of MUC5AC and clinicopathological factors in gastric cancer 
The expression of MUC5AC does not constitute a prognostic factor in our study, the 
survival rate at 5 years being 16.3% for MUC5AC positive patients vs. 16.7% for MUC5AC 
negative patients (P = 0.5334; Graphic 6)  
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Graphic 6. Survival at 5 years according to the expression of MUC5AC  
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The average survival rates, calculated in months, were of 18 months for patients with 
MUC5AC-positive carcinomas and 16.05 months for patients with MUC5AC-negative 
carcinomas, the two values being relatively close (Graphic 7). 
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Graphic 7. Average survival rate (in months) according to the expression of MUC5AC 
4. Discussions 
The genes of mucins are expressed in normal cells and tissues. The stomach offers a very 
good example of expressing mucins. MUC1 can be identified in mucous cells of the surface 
epithelium and neck of glands at the level of the antrum, but also in the pyloric and oxyntic 
glands in the gastric body (Ho et al., 1995; Pinto-De-Sousa, 2002). The MUC5AC mucin is 
expressed strongly in the foveolar epithelium of the antrum and body and MUC5AC is 
limited to mucous neck cells of gastric body glands and pyloric glands of the antrum (Ho et 
al., 1995; Pinto-De-Sousa, 2002; Silva et al., 2002). The expression of mucins in gastric 
carcinomas is heterogeneous, including mucins synthesized normally by the gastric mucosa 
(MUC1, MUC5AC and MUC6), as well as intestinal mucins synthesized de novo (MUC2) 
(Baldus et al., 1998; Ho et al., 1993; Reis, 1997, 1998). Some authors suggested that the 
heterogeneous pattern of expression would offer information regarding the evolution of 
various forms of gastric cancer. 
The progression of tumorigenesis involves abnormalities in the expressions of cyclins and 
other cell-cycle related genes (Ioachim, 2008). Abnormalities have been found for cyclins D1, 
A, E and their co-operating partners (cyclin-dependent kinase), that promote cell cycle 
progression (Handa et al., 1999; Ioachim, 2008). These progressive factors can be inhibited 
by blockers, such as p21, p27 and p57, p16, p15 and p18. Key regulators of progression 
through the G1 phase of the cell cycle are cyclin D1, cyclin E, p53, p21 and p27 (Gamboa-
Dominguez et al., 2007; Mrena et al., 2006). Sugai et al. (2010), analyzing 190 gastric 
intramucosal differentiated-type cancers have suggested that the cellular mucin phenotypes 
are dependent on distinct cell cycle-related alteration. It was proposed a novel 
carcinogenesis model that relies on the mucin phenotype. Based on abnormalities of cell-
cycle related proteins, overexpressions of p53 and cyclin A characterize gastric phenotype 
cancers, whereas overexpression of p27 is associated with the development of intestinal-
phenotype cancers and overexpression of cyclin A with the mixt phenotype cancers. 
Mucin and mucin O-glycosylation have attracted attention for their role in the adhesion of 
bacteria, cell-cell adhesion, and cancer cell metastization (Hollingsworth & Swanson, 2004). 
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The expression of mucins is often altered in cancer, with frequent aberrant glycosylation, 
resulting immature structures and exposure of the peptide backbone (Ferreira et al.,   ;Reis et 
al., 1998). These structures are useful markers of premalignant and malignant cells. Gomez 
et al (Gomes et al., 2009) have studied the pattern of expression of UDP-N-acetyl-D-
galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 (ppGal NAc-T6) in gastric 
mucosa, intestinal metaplasia and gastric carcinoma. ppGal NAc-T6 was expressed in 
normal mucosa (both antrum and body region), in 52% of the cases with intestinal 
metaplasia and had a heterogeneous expression in gastric carcinomas, being present in 79% 
of case. Its expression in gastric carcinomas was associated with venous invasion. 
In our study we aimed to evaluate the profile of mucins in gastric carcinomas in the study 
group, through immunohistochemical reactions, using monoclonal anti-MUC1, MUC2, and 
MUC5AC antibodies. The purpose of the study is to compare the expression of mucins with 
clinicopathological factors and with the outcome of patients. In accordance with other works 
(Pinto-De-Sousa, 2002), the data obtained show that the immunohistochemical expression of 
mucins is associated with some characteristics of differentiation in gastric carcinomas. We 
noted the alteration of the profile of normal gastric mucins and the overexpression of 
intestinal mucin in the various forms of cancer. 
In the peritumoral mucosa, the MUC1 immunoreactivity was detected in the specialized 
glands of the gastric body, in the pyloric glands, and at the level of the antrum (in surface 
mucous cells and neck mucous cells). Amongst the carcinomas studied we identified 41 
cases with positive immunoreactions for MUC1, representing 67.2%. Using two specific 
monoclonal antibodies, Pinto-de-Sousa (2002) obtained positive reactions in 89% of cases 
with HFMG1 antibody and 50 of cases with SM3 antibody (which recognizes only the non-
glycosylated forms of MUC1). Generally, the immunoreactivity for MUC1 varies in different 
studies between 24.3% and 100% (Gürbüz et al., 2002). The MUC1 antigen was expressed in 
most cases at the apical pole of cells and intraluminally, and occasionally diffusely 
intracytoplasmatic. Our results do not show a relationship between the expression of MUC1 
and the gender of patients or the location of tumors, but reveal a greater immune positivity 
in patients with ages over 61 (78.1%), in comparison with patients under 60 years of age 
(55.2%) (borderline statistical significance). 
Classifying the tumors studied, according to Lauren, we noticed a greater frequency of 
MUC1 positive immunoreactions in carcinomas with glandular differentiation (73.7%), 
although without reaching statistical significance. Concordant results were obtained by 
Gürbüz Y et al. (2002), Lee HS et al. (2001), Machado JC et al. (2000), Reis CA et al. (1998), 
Utsunomiya T et al. (1998). The diffuse type of carcinoma became positive in 53% of cases, 
and for the non-classifiable type we obtained an intermediate value (66.7%). Reis CA et al. 
(1998) note the significant association between the immune reactivity of SM3 and the non-
classifiable gastric carcinoma. 
In our study, the differences in MUC1 expression between various histological types were 
not statistically significant. Also, in the study of Pinto-De-Sousa et al (2002), the expression 
of HMFG1 and SM3 antibodies was not correlated with histological forms of gastric cancer. 
The immunohistochemical expression of MUC1 is not correlated with the tumor histological 
grade and lymphovascular invasion. The G1 carcinomas became positive for MUC1 in 100% 
of cases, but the result obtained could be influenced by the small number of cases included 
in this category. 
No correlation results from our study between the MUC1 immunoreaction and the level of 
tumor invasion (pT stage), the presence of distance metastases (pM stage) and pTNM 
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staging. We noted, however, a greater number of positive immune reactions in cases with 
lymph node metastases (31 carcinomas – 72.1%), in comparison with tumors without lymph 
node metastases (10 cases – 55.6%), but without statistical significance. The correlation 
between MUC1 positivity and the presence of lymph node metastasis was observed by 
Zhang HK et al. (2004), together with the association between MUC1 and the advanced age 
of patients with gastric tumors of large dimensions. 
In epithelial cancer cells, MUC1 is over-expressed, aberrantly glycosylated with short 
oligosaccharides and also loses its apical polarization and becomes expressed over the entire 
cell surface (Hilkens et al., 1992; Kim & Gum, 1996; Lloyd et al., 1996; Wesseling et al., 1996). 
MUC1 is an endogenous ligand of galectin-3 (an apoptosis inhibitor) in cancer cells (colon 
cancer), the interaction occurring via binding the galectin-3 to the oncofetal Thomsen-
Friedenreich carbohydrate (TF) antigen on MUC1 (Yu et al., 2007). The increased expression 
of MUC1 and TF antigen are both associated with high metastatic potential of the cancer cell 
and poor prognosis (Nakamori et al., 1994). Over-expression of MUC1 promotes tumor cell 
release from primary tumor sites by inhibiting E-cadherin-mediated cell-cell and integrin-
mediated cancer extracellular matrix interactions (Kondo et al., 1998). Thus, MUC1 may 
promote the formation of cancer cell aggregates/emboli and prolong the survival of 
disseminated cells in the circulation and contributes to cancer cell haematogenous 
dissemination (Zhao et al., 2010). 
The role of MUC1 in invasion and metastasis has been shown in different models. The 
cytoplasmic tail of MUC1 was reported to enhance the invasion in breast cancer cells 
expressing wild-type GSK-3ǃ and ǃ-catenin (Lillehoj et al, 2003), suggesting possible 
interactions between these proteins. MUC1 expression is associated with increased steady-
state levels of ǃ-catenin in the cytoplasm and nucleus of breast carcinoma cells by blocking 
the GSK-3ǃ-mediated phosphorylation of ǃ-catenin, and preventing proteosomal 
degradation (Schroeder et al., 2003). It is possible that the cytoplasmic tail of MUC1 enables 
interaction between different regulators or alternatively might compete for or sequester ǃ-
catenin. In some cell types, the MUC1 cytoplasmic tail is also involved in the transcriptional 
activation of ǃ-catenin-TCF-binding sites and transcriptional activation of cyclin D1 (Huang 
et al., 2005). MUC1 may play an antiapoptotic role in response to cellular stresses by 
stimulating Akt and the antiapoptotic protein Bcl-X to attenuate genotoxin-induced 
apoptosis (Raina et al., 2004). Recent reports suggest that this MUC1-mediated 
carcinogenesis is likely through the TGF-ǂ signaling pathway (Pochampalli et al., 2007). 
MUC1 is immunogenic in its hypoglycosylated form expressed on tumors, and the tumor-
bearing patients generate both cellular and humoral immune responses to this antigen 
(Coronella-Wood & Hersh, 2003; Vlad et al., 2004). High levels of anti-MUC1 antibodies are 
associated with a better prognosis in some adenocarcinomas (Kurtenkov et al., 2007; Silk & 
Finn, 2007), an observation that has made MUC1 an attractive candidate for vaccines against 
these malignancies. Prophylactic vaccination is the most desirable strategy to prevent 
malignant diseases. Several vaccine trials involving MUC1 have been conducted, but none 
have resulted in therapeutically beneficial immune responses (Silk & Finn, 2007). 
Identification and understanding of the host factors that influence naturally occurring 
immune responses is an important prerequisite to successfully designing a vaccine that 
would induce therapeutic responses.  
For MUC1 there are significant interindividual differences in naturally occurring antibody 
responses (Cramer et al., 2005). Recent studies in humans have shown that immune 
responsiveness to a variety of antigens- infectious agents, vaccines, autoantigens, including 
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some tumor-associated antigens- are associated with particular GM and KM allotypes, 
hereditary antigenic determinants of  Ǆ and κ chains, respectively (Kameda et al., 1998; 
Pandey, 2001; Pertovaara et al., 2004). Pandey et al. (2008) have studied 169 Caucasian 
subjects with gastric cancer that were allotyped for several GM and KM markers. Their 
results have revealed that GM 3 23 5,13 phenotype is highly significantly associated with 
MUC1 IgG levels; subjects with this phenotype had lower antibody levels compared with 
those having other phenotypes. This phenotype had an interactive effect with KM 
phenotypes on the levels of IgG antibodies to this antigen. Association of non- GM 3 23 5,13 
phenotypes with high responsiveness to MUC1 could aid in identifying subjects who are 
more likely to benefit from MUC1-based vaccines. For individuals with the low responder 
phenotype, MUC1 could be fused with appropriate adjuvants, such as heat shock proteins, 
in order to conceive a vaccine that could potentially generate high antibody responses in the 
majority of population (Li et al., 2006; Pandey et al., 2004). 
In accordance with Reis CA et al (1998) and Baldus SE at al (1998), our results regarding the 
survival of patients at 5 years prove the association between the overexpression of MUC1 
and the worse prognosis. Patients with carcinomas which became positive for MUC1 
survived at 5 years significantly less (12.2%) than patients with MUC1-negative carcinomas 
(25%). A significant difference was also obtained by calculating, in months, the average 
survival in the postoperative period: for patients with MUC1-positive carcinomas – 12 
months; for patients with MUC1-negative carcinomas – 28.5 months. 
The results regarding the prognostic role for the immunohistochemical expression of MUC1 
are contradictory. Studying a group of 94 gastric carcinomas, Pinto-De-Sousa et al. (2002) 
did not observe a relationship between MUC1 and the prognosis of patients. 
The immunohistochemical reactions performed with the anti-MUC5AC antibody 
demonstrated a strong expression in the foveolar epithelium of the antrum and gastric body, 
as well as in the cytoplasms of malignant cells in 43 gastric carcinomas (70.5%). 
The results obtained do not show a relationship between the age or gender of patients and 
the expression of MUC5AC. The analysis of MUC5AC according to the location of tumors 
demonstrated a frequent immunoreactivity of the antibody in antral carcinomas (80.6%), but 
without reaching statistical significance. Cardial tumors did not express the MUC5AC 
antigen. 
The diffuse type of gastric carcinoma, as well as “signet-ring” cell carcinoma, presented in a 
very high percentage (88.2%) MUC5AC-positive immune reactions. Our results seem to 
show that MUC5AC is expressed mostly in the signet-ring cell carcinoma, but the 
differences between the histological subtypes did not reach statistical significance. The 
association between the expression of MUC5AC and the diffuse type carcinoma is 
mentioned also by other authors (Pinto-De-Sousa et al., 2002), suggesting keeping certain 
features of tumor differentiation in the gastric mucosa. Some studies signal the strong 
correlation between the immunoreactivity of MUC5AC and the tumors with infiltrative 
growth pattern (Gürbüz et al., 2002). This association reflects the modality of growth and 
invasion in diffuse type carcinomas. 
We did not note a relationship between the tumor histological grade, the lymphovascular 
invasion and the expression of MUC5AC. Our results did not show the existence of a 
correlation between the level of tumor invasion, the presence of lymph node or distance 
metastases, the pTNM stage, and the immunohistochemical expression of MUC5AC. 
In accordance with Pinto-De-Sousa`s results (2002), the expression of MUC5AC in our study 
does not constitute a prognostic factor, survival rates at 5 years being of 16.3% for patients 
www.intechopen.com
 Immunohistochemical Profile of Mucins in Gastric Carcinoma 
 
227 
with MUC5AC-positive carcinomas, and 16.7% for patients with MUC5AC-negative 
carcinomas. In the studies of Reis CA et al. (1998) and Hatori & Kushima (2002), the 
expression of MUC5AC was much frequently observed in incipient gastric carcinomas 
(100%) in comparison with advanced carcinomas (58.6%). The authors conclude that all 
gastric carcinomas are characterized by a “gastric” phenotype in the first stages of 
tumorigenesis. The average survival rates, calculated in months, were of 18 months for 
patients with MUC5AC-positive carcinomas, and 16.05 months for patients with MUC5AC-
negative carcinomas, the two values being relatively close. 
Several papers have described the relationship between mucin and pancreatic cancer, de 
novo expression of MUC5AC frequently occurring in intraductal papillary mucinous 
tumors and pancreatic adenocarcinoma (Kanno et al., 2006; Kim et al., 2002), while Takikita 
et al. (2009) reported that borderline statistically significant associations are seen between 
MUC5AC positivity and shorter survival time in patients with pancreatic cancer. Yamazoe S 
et al. (2010) demonstrated that suppression of MUC5AC reduced adhesive, invasive and 
metastatic potential of pancreatic cancer cell lines. MUC5AC might contribute to the 
progression of pancreatic cancer by inducing adhesiveness and invasiveness in extracellular 
matrix via VEGF overexpression.  
Immune positivation for MUC2 was observed in our study only in malignant cells 
(intracytoplasmic) and in goblet cells in foci of intestinal metaplasia of peritumoral gastric 
mucosa. We did not note the MUC2 synthesis in epithelial cells of the normal gastric 
mucosa. Our results show that MUC2 intestinal mucine is expressed aberrantly in 25 gastric 
carcinomas (40% of cases). 
Tumors developed at the level of the cardia expressed MUC2 in 100% of cases, suggesting 
the existence of a possible correlation between the overexpression of MUC2 and the cardial 
location of gastric carcinomas, but these data needs further confirmation by a larger number 
of cases. 
According to the Lauren classification, we noted a greater immune positivation in intestinal-
type carcinomas and mixed-type in comparison with diffuse-type carcinomas, but without 
reaching statistical significance. 
In accordance with results of other studies (Pinto-De-Sousa et al., 2002; Reis et al., 2000), 
overexpression of MUC2 is correlated significantly (borderline statistical significance) with 
mucinous adenocarcinoma, being identified in 87.5% of cases. Overexpression of MUC2 was 
also described in colonic, pancreatic, mammary and ovarian mucinous carcinomas (Hanski 
et al., 1997). Immunoreactivity of MUC2 is tightly correlated with the presence of goblet 
cells. This fact suggests that the predominant cellular population in mucinous carcinoma 
consists of goblet cells. 
Choi JS et al (2009) have studied human mucin gene expression and mucin phenotypes in 
mucinous and non-mucinous gastric carcinomas. Mucin gene expression profiles differed in 
nucinous vs. non-mucinous tumors. MUC2 was related distinctively to mucinous 
carcinomas and was expressed in 95.5% of these tumors, whereas it was observed in only 
33.4% of non-mucinous carcinomas, suggesting that MUC2 is closely related to the 
mucinous histology and that it may play a role in the histogenesis of mucinous gastric 
carcinomas. MUC2 is expressed in normal colonic and small intestinal mucosa, but is not 
expressed in normal gastric mucosa. When intestinal metaplasia occurs in the stomach, 
MUC 2 is expressed in the goblet cells. In this study, mucinous gastric carcinomas were 
characterized by MUC1 negativity, MUC2 positivity, MUC5AC negativity, and MUC6 
negativity compared with non-mucinous tumors. Mucinous carcinomas were categorized as 
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intestinal mucin phenotype in 60.9%, mixed phenotype in 34.6%, and gastric phenotype in 
2.3%. Patients who had the gastric or mixed phenotype had a shorter median survival than 
patients who had the intestinal phenotype, although the survival curves were not 
significantly different. 
Data obtained in our study are not suggestive for a relationship between the tumor 
histological grade or lymphovascular invasion and the immunohistochemical expression of 
MUC2. Based on the results obtained, we cannot state the existence of a relationship 
between the pT, pN, pM, pTNM factors and the MUC2 immunoreaction in the gastric 
carcinomas examined. 
The immunohistochemical expression of MUC2 does not influence survival at 5 years of 
patients, survival rates at 5 years being of  16% for patients with MUC2-positive carcinomas 
and 16.7% for patients with MUC2-negative carcinomas. Average survivals calculated in 
months show the lack of correlation between the prognosis of patients and the 
immunohistochemical expression of MUC2 (16 months for patients with MUC2-positive 
carcinomas and 18.4 months for patients with MUC2-negative carcinomas). 
Immunohistochemical evaluation of the pattern of mucins can be considered an important 
method of interpretation and understanding of various clinical and pathological entities of 
gastric cancer. The expression of the intestinal mucin MUC2 was shown much more 
frequently in carcinomas located at the level of the cardia (100%), in comparison with antral 
tumors (41.9%), gastric body tumors (40%), pangastric tumors (30%), or tumors developed 
at the level of the gastric blunt (25%). This result suggests that cardial tumors are diagnosed 
and resected in advanced pTNM stages. In accordance with Ho and colab. (28), the data 
obtained in our study confirm the hypothesis according to which the heterogeneous 
expression of mucins and the “de novo” synthesis of non-gastric mucins correspond to 
advanced stages of gastric cancer. 
Gastric carcinomas located at the level of the antrum express MUC5AC in a significantly 
greater proportion (80.6%) in comparison with tumors of the gastric body (66.7%), 
pangastric (60%) or cardial (0%). This high percentage could be due either to the slightly 
more advanced tumor stage in comparison with proximal carcinomas, either to the high 
frequency of diffuse-type carcinomas, located in the distal stomach. 
5. Conclusions 
The immunohistochemical evaluation of the pattern of mucines can be considered as an 
important method of interpreting and understanding the various clinical and pathological 
entities of gastric cancer. 
The immunohistochemical expression of mucines is correlated with the histological type of 
gastric carcinoma (MUC1 with carcinomas with glandular differentiation, MUC2 with the 
mucinous carcinoma, and MUC5AC with the diffuse type of gastric carcinoma and the ring 
cell carcinoma). Our results suggest the different carcinogenesis of these histological types. 
In our study, the immunohistochemical expression of MUC1 constitutes an important 
prognostic factor, survival at 5 years of patients with MUC1-positive carcinomas being 
significantly lower than survival at 5 years of patients with MUC1-negative carcinomas. 
Patients with MUC1 positive carcinomas were about two times more likely to die than those 
with MUC1 negative carcinomas. 
The results obtained show that the immunohistochemical expressions of MUC2 and 
MUC5AC do not constitute prognostic factors in assessing the patients with gastric cancers. 
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According to the immunoreactivity of MUC2, the gastric mucinous carcinoma develops 
from a cellular population consisting predominantly of goblet cells. 
The data obtained in our study confirms the hypothesis according to which the 
heterogeneous expression of mucines and the “de novo” synthesis of non-gastric mucines 
correspond to advanced stages of gastric cancer. 
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